研報掘金丨華創證券:維持新產業“推薦”評級,目標價約67元
華創證券研報指出,新產業(300832.SZ)24年歸母淨利潤18.28億元(+10.57%),25Q1歸母淨利潤4.38億元(+2.65%)。國內市場大型機裝機佔比持續提升,集採導致試劑業務短暫承壓。海外持續快速增長。按地區劃分,24年歐洲、拉美地區實現增長提速,亞太地區則繼續保持穩健增長趨勢。24年印度市場收入突破2億元,已在14個核心國家建立運營體系。參考可比公司,給予公司2025年25倍PE,對應目標價約67元,維持“推薦”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.